BROENNIMAN EDWARD G 4

What Happened

• Edward G. Broenniman, a director of Aethlon Medical, received a grant of 21,815 restricted stock units (RSUs) on April 17, 2026. The grant is reported at an implicit per-share value of $2.29, for a total reported value of $49,956. This is an award/grant (transaction code A), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-04-17; Filing date: 2026-04-21 (filed within the SEC’s 2-business-day window).
• Shares/units granted: 21,815 RSUs; reported price: $2.29 per share; reported total value: $49,956.
• Shares owned after transaction: Not disclosed in the provided excerpt of the filing.
• Footnote: The RSUs vest in four equal quarterly installments on June 30, 2026; Sept 30, 2026; Dec 31, 2026; and Mar 31, 2027, subject to continued service.

Context

• RSU grants are a form of compensation and typically vest over time; they are not immediate purchases or signals of buying/selling activity. Do not interpret the award alone as a market endorsement—it's standard executive/board compensation unless combined with other trading activity.